Get the Stockscreener App
25.30
1.77%
0.44
After Hours:
25.17
-0.13
-0.51%
Damora Therapeutics Inc stock is traded at $25.30, with a volume of 166.30K.
It is up +1.77% in the last 24 hours and down -2.32% over the past month.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
See More
Previous Close:
$24.86
Open:
$25.02
24h Volume:
166.30K
Relative Volume:
0.70
Market Cap:
$1.56B
Revenue:
-
Net Income/Loss:
$-209.84M
P/E Ratio:
-5.5361
EPS:
-4.57
Net Cash Flow:
$-6.73M
1W Performance:
+2.85%
1M Performance:
-2.32%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$24.86
$26.23
1-Week Range:
$23.78
$26.23
52-Week Range:
$16.50
$28.76
Damora Therapeutics Inc Stock (DMRA) Company Profile
Name
Damora Therapeutics Inc
Sector
Industry
Phone
(781) 281-9020
Address
221 CRESCENT STREET, WALTHAM
Compare DMRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DMRA
Damora Therapeutics Inc
|
25.30 | 1.53B | 0 | -209.84M | -6.73M | -4.57 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Damora Therapeutics Inc Stock (DMRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Initiated | RBC Capital Mkts | Outperform |
| Mar-25-26 | Initiated | Evercore ISI | Outperform |
| Feb-17-26 | Initiated | UBS | Buy |
| Jan-07-26 | Initiated | Leerink Partners | Outperform |
| Dec-01-25 | Initiated | Guggenheim | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | BofA Securities | Buy |
| Nov-23-20 | Initiated | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | SVB Leerink | Outperform |
View All
Damora Therapeutics Inc Stock (DMRA) Latest News
Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
DMRA Technical Analysis & Stock Price Forecast - Intellectia AI
Will Widening Net Losses And New Finance Chief Change Damora Therapeutics' (DMRA) Narrative - Sahm
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Chart and Price History 2026 - MarketBeat
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Forecast and Price Target 2026 - MarketBeat
Point72-backed entities report 1.19M shares in Damora (DMRA) - Stock Titan
Damora Therapeutics (DMRA) filing: Jain Global group reports 0.0% stake - Stock Titan
Avoro Capital (DMRA) and Dr. Aghazadeh report 3.78M shares (6.27%) - Stock Titan
Damora Therapeutics, Inc. Common Stock (DMRA) Financials 2026Income Statement and Balance Sheet - MarketBeat
Damora Therapeutics, Inc. Stock 12‑Month Price Target Cut to $44.5, Implies 93% Upside - TradingView
Damora's $533M Gambit: New Leadership Targets Rare Blood Cancers - BriefGlance
RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
DMRA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
Damora Therapeutics 1Q 2026: Net loss $27.8M — 10-Q Summary - TradingView
Damora funds 3 blood-disorder drugs with $533M cash into 2029 - Stock Titan
Damora Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Damora Therapeutics (DMRA) ramps mutCALR R&D with major cash raise - Stock Titan
Damora Therapeutics, Inc. Common Stock (DMRA) Short Interest & Short Float | Updated May 2026 - MarketBeat
Damora Therapeutics, Inc. Common Stock (DMRA) Earnings Date and Reports 2026 - MarketBeat
Number of shareholders of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
What Damora Therapeutics (DMRA)'s CEO Shake-Up and Finance Refresh Means For Shareholders - Yahoo Finance
Damora Therapeutics (DMRA) SVP reports 312,535-share stock option grant - Stock Titan
What Damora (DMRA) is doing that smarter investors notice (Investors Pile In) 2026-05-08IV Spike - Newser
A Look At Damora Therapeutics (DMRA) Valuation After Recent Share Price Momentum And Negative Equity Signals - Sahm
Damora Therapeutics Appoints Jennifer Jarrett as New Chief Executive - HarianBasis.co
Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer - Yahoo Finance
Assessing Damora Therapeutics (DMRA) Valuation After CFO Transition And Recent Share Price Momentum - Yahoo Finance
Damora Therapeutics Announces CFO Transition to Internal Leader - TipRanks
5 Best Performing NASDAQ Stocks According to Wall Street Analysts - Insider Monkey
Damora Therapeutics: Lori Firmani to cease serving as CFO effective May 1, 2026SEC filing - marketscreener.com
Damora Therapeutics (NASDAQ: DMRA) replaces CFO, elevating SVP finance - Stock Titan
Damora Therapeutics Inc Stock (DMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):